Comprehensive Drug Testing of Patient-derived Conditionally Reprogrammed Cells from Castration-resistant Prostate Cancer

European Urology

Volumn 71, Issue 3, 2017, Pages 319-327

  Saeed, Khalid ^a   Rahkama, Vesa ^a   Eldfors, Samuli ^a   Bychkov, Dmitry ^a   Mpindi, John Patrick ^a   Yadav, Bhagwan ^a   Paavolainen, Lassi ^a   Aittokallio, Tero ^a   Heckman, Caroline ^a   Wennerberg, Krister ^a   Peehl, Donna M ^b   Horvath, Peter ^a,c   Mirtti, Tuomas ^a,d   Rannikko, Antti ^d   Kallioniemi, Olli ^a   Östling, Päivi ^a   af Hällström, Taija M ^a  

^a UNIVERSITY OF HELSINKI   (Finland)

^b STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c INSTITUTE OF BIOCHEMISTRY   (Hungary)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

Author keywords

Castration resistant prostate cancer; Drug sensitivity testing; Navitoclax; Patient derived cultures; Reprogrammed cells

Indexed keywords

ABIRATERONE; CASPASE 3; CYTOKERATIN 18; CYTOKERATIN 5; DOCETAXEL; GEMCITABINE; MEPACRINE; NAVITOCLAX; OXALIPLATIN; PACLITAXEL; PROTEIN BCL XL; PROTEIN MCL 1; RETINOID; RNA; TAXANE DERIVATIVE; ANDROGEN RECEPTOR; ANILINE DERIVATIVE; ANTINEOPLASTIC AGENT; AR PROTEIN, HUMAN; BEXAROTENE; KALLIKREIN; KALLIKREIN-RELATED PEPTIDASE 3, HUMAN; PLATINUM COMPLEX; PROSTATE SPECIFIC ANTIGEN; RETINOIC ACID; SULFONAMIDE; TETRALIN DERIVATIVE;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; CELL GROWTH; CELL VIABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SCREENING; DRUG SENSITIVITY; GENOMICS; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MALE; NUCLEAR REPROGRAMMING; PHASE 2 CLINICAL TRIAL (TOPIC); POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROSTATE TISSUE; PROTEIN EXPRESSION; RNA SEQUENCE; TRANSCRIPTOMICS; CELL REPROGRAMMING TECHNIQUE; DRUG EFFECTS; METABOLISM; PERSONALIZED MEDICINE; TUMOR CELL CULTURE;

ANILINE COMPOUNDS; ANTINEOPLASTIC AGENTS; CELLULAR REPROGRAMMING TECHNIQUES; DRUG SCREENING ASSAYS, ANTITUMOR; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; KALLIKREINS; KERATIN-18; KERATIN-5; MALE; ORGANOPLATINUM COMPOUNDS; PRECISION MEDICINE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS, CASTRATION-RESISTANT; QUINACRINE; RECEPTORS, ANDROGEN; SULFONAMIDES; TETRAHYDRONAPHTHALENES; TRETINOIN; TUMOR CELLS, CULTURED;

EID: 84965048641     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2016.04.019     Document Type: Article

References (25)

1. [1] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 65 (2014), 467–479.
2. [2] Heidenreich, A., Bastian, P.J., Bellmunt, J., et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 65 (2014), 124–137.
3. [3] Pagliarulo, V., Bracarda, S., Eisenberger, M.A., et al. Contemporary role of androgen deprivation therapy for prostate cancer. Eur Urol 61 (2012), 11–25.
4. [4] Montgomery, R.B., Mostaghel, E.A., Vessella, R., et al. Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68 (2008), 4447–4454.
5. [5] de Bono, J.S., Logothetis, C.J., Molina, A., et al. Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364 (2011), 1995–2005.
6. [6] Scher, H.I., Fizazi, K., Saad, F., et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367 (2012), 1187–1197.
7. [7] Tannock, I.F., de Wit, R., Berry, W.R., et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med 351 (2004), 1502–1512.
8. [8] de Bono, J.S., Oudard, S., Ozguroglu, M., et al. Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial. Lancet 376 (2010), 1147–1154.
9. [9] Heidenreich, A., Scholz, H.J., Rogenhofer, S., et al. Cabazitaxel plus prednisone for metastatic castration-resistant prostate cancer progressing after docetaxel: results from the German compassionate-use programme. Eur Urol 63 (2013), 977–982.
10. [10] Schrader, A.J., Boegemann, M., Ohlmann, C.H., et al. Enzalutamide in castration-resistant prostate cancer patients progressing after docetaxel and abiraterone. Eur Urol 65 (2014), 30–36.
11. [11] Parker, C., Nilsson, S., Heinrich, D., et al. Alpha emitter radium-223 and survival in metastatic prostate cancer. N Engl J Med 369 (2013), 213–223.
12. [12] Uzgare, A.R., Xu, Y., Isaacs, J.T., In vitro culturing and characteristics of transit amplifying epithelial cells from human prostate tissue. J Cell Biochem 91 (2004), 196–205.
13. [13] van Leenders, G.J., Schalken, J.A., Epithelial cell differentiation in the human prostate epithelium: implications for the pathogenesis and therapy of prostate cancer. Crit Rev Oncol Hematol 46:Suppl (2003), S3–S10.
14. [14] Bonkhoff, H., Remberger, K., Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth: a stem cell model. Prostate 28 (1996), 98–106.
15. [15] Qin, J., Liu, X., Laffin, B., et al. The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration. Cell Stem Cell 10 (2012), 556–569.
16. [16] Liu, X., Ory, V., Chapman, S., et al. ROCK inhibitor and feeder cells induce the conditional reprogramming of epithelial cells. Am J Pathol 180 (2012), 599–607.
17. [17] Chua, C.W., Shibata, M., Lei, M., et al. Single luminal epithelial progenitors can generate prostate organoids in culture. Nat Cell Biol 16 (2014), 951–961.
18. [18] Gao, D., Vela, I., Sboner, A., et al. Organoid cultures derived from patients with advanced prostate cancer. Cell 159 (2014), 176–187.
19. [19] Pemovska, T., Kontro, M., Yadav, B., et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov 3 (2013), 1416–1429.
20. [20] Yadav, B., Pemovska, T., Szwajda, A., et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. Sci Rep, 4, 2014, 5193.
21. [21] Lee, J.L., Ahn, J.H., Choi, M.K., et al. Gemcitabine-oxaliplatin plus prednisolone is active in patients with castration-resistant prostate cancer for whom docetaxel-based chemotherapy failed. Br J Cancer 110 (2014), 2472–2478.
22. [22] Suprynowicz, F.A., Upadhyay, G., Krawczyk, E., et al. Conditionally reprogrammed cells represent a stem-like state of adult epithelial cells. Proc Natl Acad Sci U S A 109 (2012), 20035–20040.
23. [23] Lebedeva, I., Rando, R., Ojwang, J., Cossum, P., Stein, C.A., Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. Cancer Res 60 (2000), 6052–6060.
24. [24] Krajewska, M., Krajewski, S., Epstein, J.I., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol 148 (1996), 1567–1576.
25. [25] Stackhouse, G.B., Sesterhenn, I.A., Bauer, J.J., et al. p53 and bcl-2 immunohistochemistry in pretreatment prostate needle biopsies to predict recurrence of prostate cancer after radical prostatectomy. J Urol 162 (1999), 2040–2045.